Swedish mitochondrial medicine firm NeuroVive has announced a collaboration with China’s Sihuan Pharmaceutical Holdings (HKEx: 0460) for the development and commercialization in China of NeuroVive’s most clinically advanced products CicloMulsion (cyclosporine) and NeuroSTAT.
Sihuan is one of the largest domestic pharmaceutical companies in China and the market leader in the fast-growing Chinese cardio-cerebral vascular (CCV) drugs market. The agreement was entered into by Sihuan through its wholly-owned subsidiary Sun Moral International (HK) and by NeuroVive through its subsidiary NeuroVive Pharmaceutical Asia.
Scope of the agreement
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze